CN103830220A - Pharmaceutical composition, and applications thereof in preparation of medicines used for treating cardiovascular and cerebrovascular diseases - Google Patents
Pharmaceutical composition, and applications thereof in preparation of medicines used for treating cardiovascular and cerebrovascular diseases Download PDFInfo
- Publication number
- CN103830220A CN103830220A CN201210474876.0A CN201210474876A CN103830220A CN 103830220 A CN103830220 A CN 103830220A CN 201210474876 A CN201210474876 A CN 201210474876A CN 103830220 A CN103830220 A CN 103830220A
- Authority
- CN
- China
- Prior art keywords
- danshensu
- carthamus yellow
- yellow
- pharmaceutical composition
- carthamus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 17
- 239000003814 drug Substances 0.000 title claims abstract description 16
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 10
- 208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 10
- 230000002526 effect on cardiovascular system Effects 0.000 title claims abstract description 10
- 229940079593 drug Drugs 0.000 title abstract 2
- WLYGSPLCNKYESI-RSUQVHIMSA-N Carthamin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@@]1(O)C(O)=C(C(=O)\C=C\C=2C=CC(O)=CC=2)C(=O)C(\C=C\2C([C@](O)([C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(O)=C(C(=O)\C=C\C=3C=CC(O)=CC=3)C/2=O)=O)=C1O WLYGSPLCNKYESI-RSUQVHIMSA-N 0.000 claims abstract description 62
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 claims abstract description 54
- IAVUBSCVWHLRGE-UXEKTNMQSA-N (6e)-2,5-dihydroxy-6-[(e)-1-hydroxy-3-(4-hydroxyphenyl)prop-2-enylidene]-2,4-bis[(2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]cyclohex-4-ene-1,3-dione Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C(C(C(O)([C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C1=O)=O)=C(O)\C1=C(/O)\C=C\C1=CC=C(O)C=C1 IAVUBSCVWHLRGE-UXEKTNMQSA-N 0.000 claims abstract description 4
- ZZMASNSDVDSYKO-UHFFFAOYSA-N hydroxysafflor yellow A Natural products OCC1OC(C(O)C(O)C1O)C2=C(O)C(O)(C3OC(CO)C(O)C(O)C3O)C(=O)C(=C2O)C(=O)C=Cc4ccc(O)cc4 ZZMASNSDVDSYKO-UHFFFAOYSA-N 0.000 claims abstract description 4
- 241000208809 Carthamus Species 0.000 claims description 60
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 claims description 56
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 claims description 52
- 239000000203 mixture Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 15
- 208000031225 myocardial ischemia Diseases 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 241000628997 Flos Species 0.000 claims description 4
- 239000011347 resin Substances 0.000 claims description 4
- 229920005989 resin Polymers 0.000 claims description 4
- 229920002292 Nylon 6 Polymers 0.000 claims description 3
- 239000003463 adsorbent Substances 0.000 claims description 3
- 208000029028 brain injury Diseases 0.000 claims description 2
- 238000004440 column chromatography Methods 0.000 claims description 2
- DYQVDISPPLTLLR-HJQYTNQXSA-N Carthamin Natural products CC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@]2(O)C(=C(C=C/3C(=O)C(=C(O)[C@](O)([C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C3=O)C(=O)C=Cc5ccc(O)cc5)C(=O)C(=C2O)C(=O)C=Cc6ccc(O)cc6)O DYQVDISPPLTLLR-HJQYTNQXSA-N 0.000 abstract description 3
- 229930194268 Salvianic acid Natural products 0.000 abstract 2
- 241000700159 Rattus Species 0.000 description 19
- 239000000843 powder Substances 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 10
- 230000000302 ischemic effect Effects 0.000 description 10
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 206010061216 Infarction Diseases 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000004140 cleaning Methods 0.000 description 6
- 230000007574 infarction Effects 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 210000000269 carotid artery external Anatomy 0.000 description 5
- 210000003414 extremity Anatomy 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 238000000108 ultra-filtration Methods 0.000 description 5
- 239000003643 water by type Substances 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 4
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 210000003194 forelimb Anatomy 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 206010000117 Abnormal behaviour Diseases 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000001168 carotid artery common Anatomy 0.000 description 2
- 210000004004 carotid artery internal Anatomy 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- -1 phenol aromatic acid compound Chemical class 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000001364 upper extremity Anatomy 0.000 description 2
- 210000000707 wrist Anatomy 0.000 description 2
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical group COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- FHIDNBAQOFJWCA-UAKXSSHOSA-N 5-fluorouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 FHIDNBAQOFJWCA-UAKXSSHOSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008899 fufang danshen Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 210000003657 middle cerebral artery Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- SBNFWQZLDJGRLK-UHFFFAOYSA-N phenothrin Chemical compound CC1(C)C(C=C(C)C)C1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 SBNFWQZLDJGRLK-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000009874 shenqi Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a pharmaceutical composition composed of carthamin yellow and salvianic acid, wherein the carthamin yellow comprises 50% of 100% hydroxysafflor yellow A, and the content of 100% salvianic acid is 50%. The invention also provides applications of the pharmaceutical composition in preparation of medicines used for treating cardiovascular and cerebrovascular diseases.
Description
Summary
The invention provides the pharmaceutical composition being formed by Carthamus yellow and danshensu, the S-A Hydroxysafflor yellow A 350% that wherein Carthamus yellow contains 100%>, 100%> content of Danshensu 350%.The present invention also provides the application in the medicine of this pharmaceutical composition in preparation treatment cardiovascular and cerebrovascular disease.
Technical field
The present invention relates to a kind of pharmaceutical composition being formed by Carthamus yellow and danshensu, also relate to its application in the medicine of preparation treatment cardiovascular and cerebrovascular disease.
Background technology
Carthamus yellow is the effective ingredient extracting from Flos Carthami, there is multiple pharmacology's effects such as coronary artery dilator, blood pressure lowering, antithrombotic, anoxia enduring, immunosuppressant, see [the modern study general introduction of Carthamus yellow, Wang Huiling, China's Chinese medicine science and technology, the 5th the 5th phase of volume in 1998].
Danshensu, phenol aromatic acid compound, brown color powder or yellow powder.Be used for blood circulation promoting and blood stasis dispelling, regulating QI to relieve pain, feels oppressed for breast, angina pectoris.
The inventor, by a large amount of experimentatioies, provides a kind of pharmaceutical composition being made up of Carthamus yellow, danshensu and the application in the medicine of preparation treatment cardiovascular and cerebrovascular disease thereof.
Summary of the invention
The invention provides a kind of pharmaceutical composition being made up of Carthamus yellow, danshensu, wherein the weight ratio of Carthamus yellow and danshensu is 1:20～20:1; In Carthamus yellow, contain 100%> S-A Hydroxysafflor yellow A 350%, 100%> content of Danshensu 350%.
The invention provides the application of the pharmaceutical composition being formed by Carthamus yellow, danshensu in the medicine of preparation treatment cardiovascular and cerebrovascular disease.
The invention provides the application of this pharmaceutical composition in the medicine of preparation treatment brain injury.
The invention provides the application of this pharmaceutical composition in the medicine of preparation treatment myocardial ischemia.
Pharmaceutical composition provided by the invention can be according to preparation needs, add corresponding adjuvant, exist with tablet, pill, granule, capsule, suspension, solution, syrup, injection, cream, ointment, spray, chewing agent or patch form, be preferably freeze-dried powder.Various dosage form provided by the invention all can adopt pharmacy conventional method to be prepared from.
Pharmaceutical composition provided by the invention is when for cardiovascular and cerebrovascular disease, and its using dosage scope is 35mg-1000mg, is preferably 50mg-400mg.
Pharmaceutical composition provided by the invention, while existence with dosage form, the content of its effective ingredient is 35-400mg.
Carthamus yellow of the present invention is from Flos Carthami, to extract to separate to obtain, and preferably adopts water extracting method, with macroporous adsorbent resin column chromatography method and the combination of polycaprolactam method, obtains Carthamus yellow.Danshensu of the present invention is from Radix Salviae Miltiorrhizae, to extract to separate to obtain.
The inventor has carried out following test and has confirmed that the pharmaceutical composition being made up of Carthamus yellow and danshensu, in the effect of preparing in the medicine for the treatment of cardiovascular and cerebrovascular disease, has synergism.
The specific embodiment:
Preparation example 1: the preparation of Carthamus yellow, danshensu
Get flos carthami 5kg, 30 times of water gaging percolation, filter, with absorption with macroporous adsorbent resin (the volume ratio 3:1 of extracting solution and resin), with 2 column volumes of deionized water eluting, then continue with 5 column volumes of deionized water eluting, collect eluent, use again polycaprolactam, be first washed till colourlessly with deionized water, then use 95% ethanol elution of meta-alkalescence, collect eluent, in rotary evaporator, concentrate and remove ethanol, lyophilization obtains Carthamus yellow, wherein hydroxyl carthamin yellow A-containing 75.8%.
Danshensu press document [Deng Xiling, Chen Xuemin. the synthetic and pharmacological action of danshensu. land-reclaimable medical science .2002,24 (5): 362～364] described method preparation.
Preparation example 2: the freeze-dried powder that preparation is made up of Carthamus yellow and danshensu
Under cleaning condition, get Carthamus yellow 190g, danshensu 10g, be dissolved in 1000 ml waters for injection, add 100
G mannitol, stirring and dissolving, ultrafiltration, obtains apyrogenic clear liquor, by the lyophilizing of freeze-dried powder technique, makes the freeze-dried powder containing Carthamus yellow 190 mg, danshensu 10 mg.
Preparation example 4: the freeze-dried powder that preparation is made up of Carthamus yellow and danshensu
Under cleaning condition, get Carthamus yellow 10g, danshensu 190g, be dissolved in 1000 ml waters for injection, stirring and dissolving, ultrafiltration, obtains apyrogenic clear liquor, press the lyophilizing of freeze-dried powder technique, make the freeze-dried powder containing Carthamus yellow 10 mg, danshensu 190 mg.
Preparation example 5: the freeze-dried powder that preparation is made up of Carthamus yellow and danshensu
Under cleaning condition, get Carthamus yellow 20 g, danshensu 80 g, be dissolved in 1000 ml waters for injection, add 100 g low molecular dextrans, stirring and dissolving, ultrafiltration, obtains apyrogenic clear liquor, press the lyophilizing of freeze-dried powder technique, make the freeze-dried powder containing Carthamus yellow 20 mg, danshensu 80 mg.
Preparation example 6: the freeze-dried powder that preparation is made up of Carthamus yellow and danshensu
Under cleaning condition, get Carthamus yellow 80 g, danshensu 20 g, be dissolved in 1000 ml waters for injection, add 100 g low molecular dextrans, stirring and dissolving, ultrafiltration, obtains apyrogenic clear liquor, press the lyophilizing of freeze-dried powder technique, make the freeze-dried powder containing Carthamus yellow 80 mg, danshensu 20 mg.
Preparation example 7: the freeze-dried powder that preparation is made up of Carthamus yellow and danshensu
Under cleaning condition, get Carthamus yellow 25 g, danshensu 75 g, be dissolved in 1000 ml waters for injection, stirring and dissolving, ultrafiltration, obtains apyrogenic clear liquor, press the lyophilizing of freeze-dried powder technique, make the freeze-dried powder containing Carthamus yellow 25 mg, danshensu 75 mg.
Test example 1: various dose Carthamus yellow, danshensu, the impact of compositions on focal cerebral ischemia in rats damage
(1) material:
Carthamus yellow, danshensu, compositions: prepare by preparation example 1.
Red tetrazolium: Sigma company of U.S. product, is made into 4% solution with normal saline before use.
Laboratory animal: regular grade SD rat, male, body weight 280 g-350 g.
(2) method and result:
Animal is divided into sham operated rats (normal saline) at random, model control group (normal saline), nimodipine group (Nim, 1.0 mg/kg), Carthamus yellow small dose group (1.5 mg/kg), dosage group in Carthamus yellow (3.5 mg/kg), the heavy dose of group of Carthamus yellow (45 mg/kg), danshensu small dose group (2 mg/kg), dosage group in danshensu (3.5 mg/kg), the heavy dose of group of danshensu (60 mg/kg), compositions low dose [Carthamus yellow (1.5 mg/kg)+danshensu (2 mg/kg)], 10 every group of compositions heavy doses [Carthamus yellow (45 mg/kg)+danshensu (60 mg/kg)].After fasting 12 hours, chloral hydrate (350 mg/kg, i.p.) anesthesia, separates right carotid, and folder closes in neck, common carotid artery, external carotid artery proximal part and distal end ligation, and cut off centre.External carotid artery free-end is pulled to internal carotid artery in alignment, bolt line (selecting diameter 0.24 mm nylon wire, length 5.0 cm) is inserted into intracranial by external carotid artery, while meeting slight resistance, stop, insertion depth is about 2 cm.Ligation external carotid artery opening, and open common carotid artery bulldog clamp, disinfection and stitching wound, causes right side middle cerebral artery ischemia model; Sham operated rats is only carried out the separation (above experiment is all carried out at 23 ℃～25 ℃) of right carotid, internal carotid artery, external carotid artery.Postoperative each treated animal intravenous injection relative medicine.After 24 hours, press document [Liu little Guang, Xu Lina, a kind of rat brain medium-sized artery model that can evaluate thrombolytic and anti-thrombolytic, Acta Pharmaceutica Sinica, 1995,30:662] described method and standard observe and record the behavior disorder of rat: (A) carry Mus tail and observe forelimb flexing situation, as two forelimb symmetries are stretched to ground, count 0 point, count 1 point as wrist flexing appears in operation offside forelimb, elbow flexing is counted 2 points, shoulder inward turning is counted 3 points, existing wrist flexing and/or elbow flexing, have again shoulder inward turning person, counts 4 points.(B) animal is placed on plane earth, pushes away respectively both shoulders to side shifting, check resistance.As bilateral resistance equity and strong, count 0 point, resistance descender as promoted to operation offside time, according to decline degree difference be divided into gently, in, weigh three degree, count respectively 1,2 and 3 point.(C) two animal forelimbs are put on a wire netting, observed the muscular tension of two forelimbs.Two muscle of anterior limb tension force equities and strong person count 0 point.Count 1,2 and 3 point according to operation offside muscular tension decline degree difference equally.(D) animal has ceaselessly to a side person of turn-taking, and counts 1 point.According to standard scoring, full marks are 11 points, and mark is higher, represent that animal behavior obstacle is more serious.
After behavior scoring, put to death rat, get brain, remove olfactory bulb, cerebellum and low brain stem, crownly be cut into 5, brain is red tetrazolium (TTC) dyeing for sheet, after normal structure is dyed, takes on a red color, and blocking tissue is white in color, after dyeing, take a picture, ask infarct size ratio with China Aviation space flight university pathological image analysis software.Data are used
± SD represents, between organizing
fstatistical procedures is carried out in check.
Result is as shown in table 1, and ischemia is after 24 hours, and model group rat shows obvious behavior disorder, and obvious kitchen range shape ischemic region also appears in rat cerebral tissue, reaches 25% left and right of full brain.
1.5 mg/kg Carthamus yellows and 2 mg/kg danshensu groups are failed to improve rat behavior obstacle, are reduced ischemic areas; 3.5 mg/kg Carthamus yellows and 3.5 mg/kg danshensu groups have all been improved to a certain extent rat behavior obstacle, have been reduced ischemic areas.
Compositions small dose group [Carthamus yellow (1.5 mg/kg)+danshensu (2 mg/kg)] is improved very significantly rat behavior obstacle, is reduced ischemic areas, with relatively p < 0.01 of model group, and more also there is significant difference (P < 0.05) with 3.5 mg/kg Carthamus yellows, 3.5 mg/kg danshensus.In prompting combination thing, Carthamus yellow and danshensu have synergism.Compositions heavy dose [Carthamus yellow (45 mg/kg)+danshensu (60 mg/kg)] is improved extremely significantly rat behavior obstacle, is reduced ischemic areas, with relatively P < 0.001 of model group.
Table 1 Carthamus yellow, danshensu, the impact of compositions on focal cerebral ischemia in rats damage
Test example 2: Carthamus yellow, danshensu, the impact of compositions on myocardial ischemia in rats damage
(1) material:
Carthamus yellow, danshensu, compositions: prepare by preparation example 1.
Painstaking effort pellet (compound Salviae Miltiorrhizae) injection: Guizhou Shenqi Pharmaceutical Co., Ltd.
NBT (N-BT), is provided by Military Medical Science Institute's medical supply station.
Laboratory animal: regular grade Wistar rat, male, body weight 280 g-350 g.
(2) method and result:
Animal is divided into sham operated rats (normal saline) at random, model control group (normal saline), FUFANG DANSHEN ZHUSHEYE group (DS, 10 mg/kg), Carthamus yellow small dose group (1.5 mg/kg), dosage group in Carthamus yellow (3.5 mg/kg), the heavy dose of group of Carthamus yellow (45 mg/kg), danshensu small dose group (2 mg/kg), dosage group in danshensu (3.5 mg/kg), the heavy dose of group of danshensu (60 mg/kg), compositions low dose [Carthamus yellow (1.5 mg/kg)+danshensu (2mg/kg)], 10 every group of compositions heavy doses [Carthamus yellow (45 mg/kg)+danshensu (60 mg/kg)].After fasting 12 hours, ip urethane (1.2 g/kg) anesthesia, surveys limbs II lead electrocardiogram.Cut off left front fur, iodine tincture and alcohol disinfecting, along left border of sternum 1cm place, cut off thoracic wall muscle and two ribs, open rapidly thoracic cavity, expose heart, between arterial cone and left auricle, ligation left coronary artery, puts back to heart immediately, squeezes thoracic cavity air, use mosquito forceps closed-chest, cause Model Rats with Acute Myocardial Ischemia.Postoperative each treated animal intravenous injection relative medicine.Record before administration and administration after 1.5h, 3h electrocardiogram, after 6h, take out heart, after cleaning with cold saline ,-20 ℃ of refrigerator freezings spend the night.Next day, freezing heart is cut into 5 by ligation place to apex uniform thickness, immerse in freshly prepared 0.5% NBT phosphate buffer (pH 7.4).37 ℃ of water-bath jolting 10～15 min.Blot the dyeing liquor of slice surface with filter paper, separate coloured portions and the part of being unstained, weigh, compute infarct size.Infarct size (%)=infarction part weight/(non-infarction part weight+infarction part weight) × 100%.
Result demonstration, myocardial ischemia is after 6 hours, and there is obvious kitchen range shape ischemic region in model group rat heart muscle, reaches 25% left and right.1.5 mg/kg Carthamus yellows and 2 mg/kg danshensu groups are failed to improve rat electrocardio, are reduced ischemic areas; 3.5 mg/kg Carthamus yellows and 3.5 mg/kg danshensu groups all reduce rising, the minimizing ischemic areas of the limb lead electrocardiogram J point being caused by myocardial ischemia to a certain extent; Compositions small dose group [Carthamus yellow (1.5 mg/kg)+danshensu (2 mg/kg)] reduces rising, the minimizing ischemic areas of limb lead electrocardiogram J point very significantly, with relatively P < 0.01 of model group, and more also there is significant difference (P < 0.05) with 3.5 mg/kg Carthamus yellows, 3.5 mg/kg danshensus; Compositions heavy dose [Carthamus yellow (45 mg/kg) danshensu (60 mg/kg)] reduces rising, the minimizing ischemic areas of limb lead electrocardiogram J point extremely significantly, with relatively P < 0.001 of model group.
Claims (6)
1. a pharmaceutical composition, is made up of Carthamus yellow and danshensu, and its weight ratio is 1:20～20:1; Wherein in Carthamus yellow, contain 100%> S-A Hydroxysafflor yellow A 350%, 100%> content of Danshensu 350%.
2. require the compositions described in 1 according to right profit, Carthamus yellow is from Flos Carthami, to extract to separate to obtain, and preferably adopts water extracting method, with macroporous adsorbent resin column chromatography method and the combination of polycaprolactam method, obtains Carthamus yellow.
3. compositions according to claim 1, danshensu is from Radix Salviae Miltiorrhizae, to extract to separate to obtain.
4. the application of the arbitrary described compositions of claim 1-3 in the medicine of preparation treatment cardiovascular and cerebrovascular disease.
5. the application of stating according to claim 4, the application of said composition in the medicine of preparation treatment brain injury.
6. the application of stating according to claim 4, the application of said composition in the medicine of preparation treatment myocardial ischemia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210474876.0A CN103830220A (en) | 2012-11-21 | 2012-11-21 | Pharmaceutical composition, and applications thereof in preparation of medicines used for treating cardiovascular and cerebrovascular diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210474876.0A CN103830220A (en) | 2012-11-21 | 2012-11-21 | Pharmaceutical composition, and applications thereof in preparation of medicines used for treating cardiovascular and cerebrovascular diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103830220A true CN103830220A (en) | 2014-06-04 |
Family
ID=50794327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210474876.0A Pending CN103830220A (en) | 2012-11-21 | 2012-11-21 | Pharmaceutical composition, and applications thereof in preparation of medicines used for treating cardiovascular and cerebrovascular diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103830220A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113350357A (en) * | 2020-03-05 | 2021-09-07 | 上海市普陀区中心医院 | Application of composition of hydroxysafflor yellow A and polygala tenuifolia sapogenin in preparation of medicine for treating ischemic stroke |
-
2012
- 2012-11-21 CN CN201210474876.0A patent/CN103830220A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113350357A (en) * | 2020-03-05 | 2021-09-07 | 上海市普陀区中心医院 | Application of composition of hydroxysafflor yellow A and polygala tenuifolia sapogenin in preparation of medicine for treating ischemic stroke |
| CN113350357B (en) * | 2020-03-05 | 2022-11-01 | 上海市普陀区中心医院 | Application of composition of hydroxysafflor yellow A and polygala tenuifolia sapogenin in preparation of medicine for treating ischemic stroke |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN118436792A (en) | Natural preservatives and antimicrobial agents, including combinations thereof | |
| CN106344648A (en) | Thymus plant extract and application thereof | |
| CN101596182A (en) | Contain pharmaceutical composition, its preparation method, the purposes of salviol acid A and contain the lyophilized injectable powder and the aqueous injection of said composition | |
| CN101342274B (en) | Curculigo orchioides extract, preparation method and uses thereof | |
| CN105327071A (en) | Antineoplastic traditional Chinese medicinal composition and application thereof | |
| CN101675934B (en) | New use of saponins X of dipsacus asperoides | |
| CN103830220A (en) | Pharmaceutical composition, and applications thereof in preparation of medicines used for treating cardiovascular and cerebrovascular diseases | |
| KR101210405B1 (en) | Aspirin Resistance Therapeutic Agent Using Salviae Radix, Extracts and Compositions | |
| CN1326520C (en) | A pharmaceutical composition and application thereof in preparation of medicine for preventing or treating cerebrovascular and cardiovascular disease | |
| CN101919868B (en) | Application of forsythoside B | |
| CN100577184C (en) | Medicine composition and use thereof | |
| CN105031493B (en) | A kind of preparation method of prevention or the drug for treating swin flu and hand-foot-and-mouth disease | |
| CN103356731B (en) | Pharmaceutical composition containing Cortex Eucommiae extract and Radix Notoginseng total arasaponins and application thereof | |
| CN103110734B (en) | Traditional Chinese medicine composition for treating gynecologic inflammation and preparation method thereof | |
| CN1911219B (en) | Medicine composition, and its application | |
| CN101485671B (en) | Novel medicinal use of 8-O-acetyl shanzhiside methylester | |
| CN1868507B (en) | Medicine composition, preparation method and application thereof | |
| CN101036640A (en) | Novel medical function of cnidium monnieri lactone | |
| CN105535136A (en) | A traditional Chinese medicine composition having a bacteriostasis function, a preparing method thereof and uses of the composition | |
| CN1626075A (en) | Combination of medication and application of preparing medication for treating or preventing cardiovascular and cerebrovascular diseases | |
| CN106361811A (en) | Tongmai pharmaceutical composition and preparation method thereof | |
| CN1868508B (en) | Medicine composition, application of the same for preparing medicine to treat and prevent cardiovascular and cerebrovascular disease | |
| CN101023983A (en) | Medicine composition and use | |
| CN1331473C (en) | Application of 20(S)-ginsenoside-Rg#[3] in the preparing process of medicine for treating or preventing cardiovascular and cerebrovascular disease | |
| CN100486578C (en) | Medicine composition and its application in preparation of medicine for treating or preventing cardiovascular and cerebrovascular diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140604 |